Volume 3, Issue 3, March 2025 ISSN (E): 2938-3765

MODERN APPROACH TO TREATMENT IN ONCOLOGICAL DISEASES, THE ROLE OF IMMUNOTHERAPY

Rakhimova A. F.
Samandarova A. U.
Bukhara Innovative Medical University, student
Bukhara Innovative Medical University, student
raximovaaziza27@gmail.com
sazizabonu@inbox.ru

Abstract
Metastasis, which occurs when cancer cells disseminate from the primary tumor site to other parts of the body, is the primary cause of mortality in patients, and the recurrence of multiple metastatic tumors is an obstacle to eliminating cancer. Recent clinical studies demonstrated that patients who respond to immunotherapy have longer survival rates with lower metastatic relapse, suggesting that immunotherapy may be one of the solutions to overcome cancer metastasis. Indeed, various host immune cells not only shape the tumor microenvironment but also participate in multiple stages of metastasis. Therefore, to improve clinical outcome, it is critical to understand the immunological events associated with tumor development and progression. In this article, we summarize those events that are involved in tumor progression and discuss immunotherapies that can potentially target cancer metastasis.

Keywords: Cancer, immunotherapy, treatment, modern, nanotechnology, gene therapy.

INTRODUCTION

Oncological diseases, commonly referred to as cancer, remain one of the leading causes of mortality worldwide [1-4]. Traditional treatment options such as surgery, chemotherapy, and radiation therapy have been the cornerstone of cancer management for decades[5]. However, these methods often come with severe side effects and limited efficacy in advanced or resistant cases. Recent advances in molecular biology and immunology have paved the way for innovative treatments, particularly immunotherapy, which has demonstrated remarkable success in several cancer types [6-9]. The purpose of this paper is to provide an in-depth analysis of modern oncological treatments, emphasizing immunotherapy's role and potential.

Modern Approaches to Cancer Treatment: With advancements in technology and medical research, new approaches to cancer treatment have emerged, including:

1. **Targeted Therapy:** Utilizes drugs designed to specifically target cancer cells with minimal damage to normal cells. Includes tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and angiogenesis inhibitors[10-13].

2. **Personalized Medicine:** Tailors treatment based on genetic profiling and biomarkers. Uses companion diagnostics to select the most effective therapies for individual patients [14-16].

3. **Immunotherapy:** Stimulates or enhances the immune system to recognize and eliminate cancer cells. Involves checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and monoclonal antibodies.

4. **Gene Therapy:** Introduces genetic material into a patient's cells to fight cancer. Includes gene editing techniques such as CRISPR to modify defective genes.

5. **Nanotechnology:** Employs nanoparticles for drug delivery, improving efficacy and reducing side effects. Enhances targeted drug delivery and imaging techniques.

Materials and Methods:

This study is based on an extensive review of recent scientific literature, clinical trials, and meta-analyses related to immunotherapy in oncology. Data was collected from peer-reviewed journals, medical databases such as PubMed and ScienceDirect, and reports from major cancer research institutions. The study evaluates different immunotherapy modalities, their mechanisms of action, and their efficacy in treating various cancers [17-20]. The methodology also includes comparative analysis of immunotherapy with traditional treatment methods, assessing patient outcomes, side effects, and long-term benefits [21-25].

Results and Discussion

The analysis of recent clinical trials and studies reveals that immunotherapy has significantly improved survival rates in multiple cancer types, particularly melanoma, lung cancer, and hematologic malignancies [26-30].

Checkpoint Inhibitors have shown a response rate of up to 50% in advanced melanoma and non-small cell lung cancer. CAR-T Cell Therapy has demonstrated remission rates of over 80% in certain blood cancers like B-cell acute lymphoblastic leukemia [31-35].

Combination Therapies involving immunotherapy and chemotherapy have improved progression-free survival in several types of solid tumors. Long-Term Benefits. Unlike chemotherapy, which often leads to relapse, immunotherapy has provided durable responses, with some patients remaining cancer-free for years. High costs, immune-related side effects, and the variability in patient response remain significant barriers to widespread application [36-38].

The Role of Immunotherapy in Cancer Treatment:

Immunotherapy has revolutionized oncology by offering durable responses and improving survival rates. It operates through several mechanisms:

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Immune Checkpoint Inhibitors: Drugs like PD-1/PD-L1 (e.g., Pembrolizumab, Nivolumab) and CTLA-4 inhibitors (e.g., Ipilimumab) help the immune system recognize and attack cancer cells.

CAR-T Cell Therapy: Genetically modifies T cells to target specific cancer antigens, effectively used in hematological malignancies. FDA-approved CAR-T therapies include Kymriah, Yescarta, and Tecartus.

Cancer Vaccines: Stimulate the immune system to prevent or treat cancer. Examples include the HPV vaccine for cervical cancer and Sipuleucel-T for prostate cancer.

Monoclonal Antibodies: Engineered antibodies designed to attack specific cancer cell markers. Examples: Rituximab, Trastuzumab, and Bevacizumab.

Cytokine Therapy: Utilizes proteins like interferons and interleukins to enhance immune responses. Includes IL-2 therapy for renal cell carcinoma and melanoma.

Advantages and Challenges of Immunotherapy:

Advantages*:*

- Provides long-term remission in certain cancers, such as melanoma and lung cancer.
- Fewer side effects compared to traditional chemotherapy.
- Effective in cancers that are resistant to conventional treatments.
- Enhances the immune system's memory, leading to prolonged protection.

Challenges*:*

- High cost of treatment, limiting accessibility.
- Potential for immune-related adverse effects, such as inflammation and autoimmune reactions.
- Not all patients respond to immunotherapy due to tumor heterogeneity.
- Development of resistance in some cases, necessitating combination therapies.

Combination Therapy Strategies: To enhance the effectiveness of immunotherapy, combination approaches are being explored:

Immunotherapy + Chemotherapy: Increases antigen presentation and enhances immune response.

Immunotherapy + Targeted Therapy: Reduces resistance and improves tumor targeting.

Immunotherapy + Radiation Therapy: Induces immunogenic cell death and enhances tumor immunogenicity.

Multi-Agent Immunotherapy: Combines checkpoint inhibitors with other immunomodulatory agents for synergistic effects.

Future Prospects of Immunotherapy in Oncology:

Next-Generation Checkpoint Inhibitors: Developing new targets beyond PD-1/PD-L1 and CTLA-4.

Personalized Cancer Vaccines: Tailored to individual patient tumor mutations [39-42].

Advances in CAR-T and TCR-T Cell Therapy: Expanding applications beyond hematological malignancies.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Microbiome and Immunotherapy: Investigating the gut microbiome's role in modulating immune responses.

Artificial Intelligence in Oncology: Utilizing AI to predict patient responses and optimize treatment plans.

Conclusion

The modern approach to oncological treatment has transformed patient outcomes, with immunotherapy playing a pivotal role in improving survival rates and quality of life. Despite its challenges, ongoing research continues to refine immunotherapy strategies, aiming for more effective and accessible treatments. The future of cancer treatment lies in the combination of immunotherapy with other modalities to achieve personalized and precision medicine. By integrating advanced scientific innovations, immunotherapy holds immense potential in redefining cancer care and ultimately improving patient survival rates and overall health outcomes.

References:

1. World Health Organization. Novel Coronavirus (2019-nCoV) situation reports. https://www.worldometers.info/coronavirus/ Accessed: 28 Sept. 2021.
2. Oblokulov A. R., Musaeva DM, Elmuradova AA (2020) Clinical and epidemiological characteristics of the new coronavirus infection (COVID-19). // New Day in Medicine. No2 (30/2) p.110-115.
3. Bikdeli B , Madhavan MV, Jimenez D et al. COVID- 19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. JACC. 2020. doi:10.1016/j.jacc.2020.04.031 .
4. Husenova Z. Z, & Oblokulov A. R. (2021). Clinical and epidemiological characteristics of patients with severe form of COVID-19. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES, 2(3), 282-285. https://doi.org/10.47494/cajmns.v2i3.213.
5. Cao Y. , Liu X., Xiong L. et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J. Med. Virol ., 2020 ; doi : 10.1002/jmv.25 822
6. Melhem A., Stem M., Shibolet O. et al, Treatment of chronic hepatitis C virus infection via antioxidants. Results of a phase clinical trial. J. CIin. Gastroenterol. 2005; 39: 737-742.
7. Okanue L, Sakamoto S., Iton Y. et al. Побочные эффекты лечения хронического гепатита С высокими дозами интер¬ферона. J. Hepatol. 1996; 25: 283-291.
8. Ibrokhimovna, M. M. . (2024). Improvement of Primary Prophylaxis and Treatment of Spontaneous Bacterial Peritonitis Complicated in Virus Etiology Liver Cirrhosis. Journal of Intellectual Property and Human Rights, 3(4), 19–25. Retrieved from http://journals.academiczone.net/index.php/jiphr/article/view/2506
9. Elmurodova A.A. (2023). Viral Hepatitis Delta: An Underestimated Threat. *Texas Journal of Medical Science*, *26*, 1–3. Retrieved from https://zienjournals.com/index.php/tjms/article/view/4610
10. Oblokulov Abdurashid Rakhimovich Mukhammadieva Musharraf Ibrokhimovna Sanokulova Sitora Avazovna Khadieva Dora Isakovna. (2023). CLINICAL AND

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

LABORATORY FEATURES OF SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH VIRAL LIVER CIRRHOSIS. Journal of Advanced Zoology, 44(S2), 3744–3750. Retrieved from http://www.jazindia.com/index.php/jaz/article/view/1716

11. Mukhammadieva M.I. (2022). Modern clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis //Texas Journal of Medical Science. – 2022.- P. 86-90
12. Abdulloev Mukhriddin Ziyodulloevich. (2023). Modern Therapy of Viral Hepatitis. Texas Journal of Medical Science, 26, 66–69. Retrieved from https://www.zienjournals.com/index.php/tjms/article/view/4636
13. Nabiyeva, Z. . (2023). CLINICAL MANIFESTATIONS OF CHRONIC DISEASES ОРГАНОВ OF THE DIGESTIVE SYSTEM IN CHILDREN. Инновационные исследования в современном мире: теория и практика, 2(15), 27–28. извлечено от https://in-academy.uz/index.php/zdit/article/view/13239
14. Mukhammadieva M.I. (2023). Вирус этиологияли жигар циррози беморларида спонтан бактериал перитонит билан асоратланишнинг профилактикаси ва давосини такомиллаштириш//Oriental Renaissance: Innovative, educational, natural and social sciences. -2023.-P.947-953.
15. Oblokulov A.R., M.I.Mukhammadieva.(2022). Clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis//Academicia Globe: Indersciense Research.-2022.- P. 210-216.
16. Khadieva Dora Isakovna. (2024). Diagnosis and Prediction of Liver Fibrosis in Chronic Viral Hepatitis C in Hiv-Infected. International Journal of Integrative and Modern Medicine, 2(6), 89–94. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/515
17. Кароматов Иномжон Джураевич, Набиева Зумрад Тухтаевна Адаптоген - элеутерококк, свободоягодник колючий (обзор литературы) // Биология и интегративная медицина. 2017. №11. URL: https://cyberleninka.ru/article/n/adaptogen-eleuterokokk-svobodoyagodnik-kolyuchiy-obzor-literatury (дата обращения: 19.12.2023).
18. Mukhammadieva Musharraf Ibrokhimovna. (2024). TREATMENT OF SPONTANEOUS BACTERIAL PERITONITIS COMPLICATED IN VIRUS ETIOLOGY LIVER CIRRHOSIS. JOURNAL OF EDUCATION, ETHICS AND VALUE, 3(6), 73–80. Retrieved from https://jeev.innovascience.uz/index.php/jeev/article/view/723
19. Sanokulova Sitora Avazovna. (2023). Factors of Development of Hepatorenal Syndrome in Patients with Liver Cirrhosis of Viral Etiology. Texas Journal of Medical Science, 26, 4–9. Retrieved from https://www.zienjournals.com/index.php/tjms/article/view/4611
20. Tukhtaboevna, M. Z. . (2022). ACUTE INTESTINAL INFECTIONS IN CHILDREN, MODERN PRINCIPLES OF CORRECTION AND RESTORATION OF WATER-ELECTROLYTE BALANCE. IJTIMOIY FANLARDA INNOVASIYA ONLAYN ILMIY JURNALI, 101–105. Retrieved from https://sciencebox.uz/index.php/jis/article/view/3249
21. Tukhtaboevna M. Z. Choosing an Antihistamine to Treat Seasonal Allergies //INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES. – 2022. – Т. 1. – №. 4. – С. 401-407.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

22. Jalilova, A.S. (2022). THE SPREAD OF CIRRHOSIS OF THE LIVER BY ETIOLOGICAL FACTORS. Oriental renaissance: Innovative, educational, natural and social sciences, 2 (6), 253-257.\
23. A. A., E., A. S., D., & A., M. S. (2022). Modern Approaches to Treatment of Chronic Giardiasis. Central Asian Journal of Medical and Natural Science, 3(2), 102-105. Retrieved from https://www.cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/631
24. Облокулов, А., & Муҳаммадиева, М. (2022). КЛИНИКО-ЛАБОРАТОРНАЯ ХАРАКТЕРИСТИКА СПОНТАННОГО БАКТЕРИАЛЬНОГО ПЕРИТОНИТА ПРИ ЦИРРОЗЕ ПЕЧЕНИ ВИРУСНОЙ ЭТИОЛОГИИИ. Журнал вестник врача, 1(3), 66–69. извлечено от https://inlibrary.uz/index.php/doctors_herald/article/view/2016
25. Oblokulova Z.I, Oblokulov A.R, & Jalilova A.S. (2022). Diagnostic Significance of Hepatic Fibrosis in Patients with Extrahepatic Chronic Viral Hepatitis C. Central Asian Journal of Medical and Natural Science, 3(3), 438-443. Retrieved from https://www.cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/806
26. Aslonova.M.R. (2022). Determination of suicidality against the background of Parasitic Diseases in children // INTERNATIONAL JOURNAL OF PHILOSOPHICAL STUDIES AND SOCIAL SCIENCES. – 2022.- P. 9-12.
27. Jalilova, A. S. (2022). Approaches to Etiotropic Therapy of Covid-19 in Outpatient Patients. INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES, 1(1), 41-44.
28. Mukhtarova Sh.A. (2022) Age-related features of clinical manifestations of giardiasis // International journal of medical sciences and clinical research 2022;17-21.
29. Jalilova A.S. (2022). FEATURES OF CLINICAL MANIFESTATIONS OF CYTOMEGALOVIRUS INFECTION IN CHILDREN. International Journal of Medical Sciences And Clinical Research, 2(09), 12–16. https://doi.org/10.37547/ijmscr/Volume02Issue09-04
30. Raximovich, O. A., Sadilloyevna, J. A., Abdulloyevna, M. S., & Farxodovich , R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. Central Asian Journal of Medical and Natural Science, 3(2), 289-294. https://doi.org/10.17605/OSF.IO/9CFP6
31. Жалилова А. С. Дилноза Саётовна Косимова. Клинико–Лабораторная Характеристика Пациентов С Covid-19 И Предиктор Антибактериальной Терапии //CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. – 2021. – С. 81-86.
32. Abdulloyevna, M. S. . (2023). Tez-Tez Kasal Bo'lgan Bolalarda O'tkir Respirator Kasalliklarning Klinik-Laboratoriya Xususiyatlari. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(12), 29–34. Retrieved from https://sciencebox.uz/index.php/amaltibbiyot/article/view/8680
33. Muxtorova, S. A. (2022). Clinical and laboratoriya features of acute respiratory disease in frequently ill children. Web of scientist: International scientific research journal, 1026-1030.
34. Mukhtarova, S. H. (2022). A.(2022) AGE-RELATED FEATURES OF CLINICAL MANIFESTATIONS OF GIARDIASIS. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES AND CLINICAL RESEARCH, 17-21.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

35. Mukhtorova Shokhida Abdulloevna. (2023). Microbiological Indicators of Patients Infected with SarsCov-2. Texas Journal of Medical Science, 21, 41–45. Retrieved from https://www.zienjournals.com/index.php/tjms/article/view/4116
36. Mukhtorova Shokhida Abdulloevna. (2023). CYTOMEGALOVIRUS INFECTIONS IN CHILDREN WITH PRIMARY AND SECONDARY IMMUNE DEFICIENCIES. Academia Science Repository, 4(06), 23–28. Retrieved from http://academiascience.com/index.php/repo/article/view/832
37. Aslonova.M.R. (2023). VITAMIN DEFICIENCY CASES RESULTING FROM PARASITIC DISEASES // Galaxy International Interdisciplinary Research Journal.-2023.-P. 404-409
38. Mukhtorova Shokhida Abdulloevna. (2023). CHARACTERISTIC FEATURES OF THE COURSE OF CITOMEGALOVIRUS INFECTION IN CHILDREN. Galaxy International Interdisciplinary Research Journal, 11(4), 484–487. Retrieved from https://giirj.com/index.php/giirj/article/view/5150..
39. Raximovich, O. A., Sadilloyevna, J. A., Abdulloyevna, M. S., & Farxodovich , R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. Central Asian Journal of Medical and Natural Science, 3(2), 289-294. https://doi.org/10.17605/OSF.IO/9CFP6
40. Ш. А, М. (2023). Профилактика Сезонного Распространения Орви Среди Детей Раннего Возраста. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(12), 22–28. Retrieved from https://www.sciencebox.uz/index.php/amaltibbiyot/article/view/8678
41. M. I., M. . (2024). Features of the Clinical Course of Virus-Associated Glomerulonephritis in Children and Adolescents. Research Journal of Trauma and Disability Studies, 3(10), 163–169. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/3676
42. Mukhammadieva M. I. (2024). PREVENTION OF COMPLICATIONS WITH SPONTANEOUS BACTERIAL PERITONITIS WITH LIVER CIRRHOSIS OF VIRAL ETIOLOGY. Web of Medicine: Journal of Medicine, Practice and Nursing, 2(12), 191–197. Retrieved from http://webofjournals.com/index.php/5/article/view/2595.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5